Standard BioTools Inc (NASDAQ:LAB) price on Wednesday, February 05, rose 3.42% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.51.
A look at the stock’s price movement, the close in the last trading session was $1.46, moving within a range at $1.445 and $1.535. The beta value (5-Year monthly) was 1.569. Turning to its 52-week performance, $3.04 and $1.21 were the 52-week high and 52-week low respectively. Overall, LAB moved -17.03% over the past month.
Standard BioTools Inc’s market cap currently stands at around $562.11 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 43.03M for the company’s revenue for the quarter, with a low and high estimate of 42.2M and 44.6M respectively. The average forecast suggests up to a 52.67% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 171.2M, representing a 60.99% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LAB is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend LAB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LAB’s current price about -11.55% and -15.99% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 40.20, while 7-day volatility ratio is 6.68% and 8.34% in the 30-day chart. Further, Standard BioTools Inc (LAB) has a beta value of 1.57, and an average true range (ATR) of 0.13. Analysts have given the company’s stock an average 52-week price target of $3.25, forecast between a low of $3.25 and high of $3.25. Looking at the price targets, the low is -115.23% off current price level while to achieve the yearly target high, price needs to move -115.23%. Nonetheless, investors will most likely welcome a -115.23% jump to $3.25 which is the analysts’ median price.
If we refocus on Standard BioTools Inc (NASDAQ:LAB), historical trading data shows that trading volumes averaged 1.81 over the past 10 days and 1.84 million over the past 3 months. The company’s latest data on shares outstanding shows there are 372.26 million shares.
The 3.16% of Standard BioTools Inc’s shares are in the hands of company insiders while institutional holders own 72.86% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.32 million on 2025-01-15, giving us a short ratio of 8.1. The data shows that as of 2025-01-15 short interest in Standard BioTools Inc (LAB) stood at 735.0 of shares outstanding, with shares short rising to 13.31 million registered in 2024-12-13. Current price change has pushed the stock -13.71% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LAB stock continues to rise going into the next quarter.
